Incidence and risk factors of drug-induced kidney injury in children: a systematic review and meta-analysis

Purpose To comprehensively summarize the incidence and risk factors of drug-induced kidney injury (DIKI) in children. Methods We systematically searched seven databases from inception to November 2022. Two independent reviewers selected studies, extracted data, and assessed the risk of bias. Meta-analyses were conducted to quantify the incidence and risk factors of DIKI in children. Results A total of 69 studies comprising 195,894 pediatric patients were included. Overall, the incidence of DIKI in children was 18.2% (95%CI: 16.4%-20.1%). The incidence of DIKI in critically ill children (19.6%, 95%CI: 15.9%-23.3%) was higher than that in non-critically ill children (16.1%, 95%CI: 12.9%-19.4%). Moreover, the risk factors for DIKI in children were intensive care unit (ICU) admission (OR = 1.59, 95% CI: 1.42–1.78, P = 0.000), treatment days (OR = 1.04, 95% CI: 1.03–1.05, P = 0.000), surgical intervention (OR = 1.43, 95% CI: 1.00–2.02, P = 0.048), infection (OR = 2.30, 95% CI: 1.44–3.66, P = 0.000), patent ductus arteriosus (OR = 4.78, 95% CI: 1.82–12.57, P = 0.002), chronic kidney disease (OR = 2.78, 95% CI: 1.92–4.02, P = 0.000), combination with antibacterial agents (OR = 1.98, 95% CI: 1.54–2.55, P = 0.000), diuretics (OR = 1.97, 95% CI: 1.51–2.56, P = 0.000), combination with antiviral agents (OR = 1.50, 95% CI: 1.11–2.04, P = 0.008), combination with non-steroidal anti-inflammatory drugs (OR = 1.79, 95% CI: 1.40–2.28, P = 0.000), and combination with immunosuppressive agents (OR = 2.84, 95% CI: 1.47–5.47, P = 0.002). Conclusion The incidence of DIKI in children is high, especially in critically ill children. Identifying high-risk groups and determining safer treatments is critical to reducing the incidence of DIKI in children. In clinical practice, clinicians should adjust medication regimens for high-risk pediatric groups, such as ICU admission, some underlying diseases, combination with nephrotoxic drugs, etc., and regularly evaluate kidney function throughout treatment.